These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 63145)

  • 1. [Simultaneous combination of adriamycin, bleomycin, cyclohexyl-chloroethyl nitrosourea with dimethyl-triazeno imidazole carboxamide in the treatment of Hodgkin's lymphoma].
    Abele R; Alberto P; Germano G; Obrecht JP; Wagenknecht L
    Schweiz Med Wochenschr; 1976 Jul; 106(28):961-3. PubMed ID: 63145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, dacarbazine and vinblastine (ABDV).
    Case DC; Young CW; Lee BJ
    Cancer; 1977 Apr; 39(4):1382-6. PubMed ID: 66972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.
    Lokich JJ; Frei E; Jaffe N; Tullis J
    Cancer; 1976 Aug; 38(2):667-71. PubMed ID: 61797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A reserve chemotherapy for Hodgkin's disease (author's transl)].
    Amiel JL; Ayed FB; Droz JP; Tursz T; Brule CH
    Nouv Presse Med; 1980 Oct; 9(37):2705-6. PubMed ID: 6159573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin.
    Levi JA; Wiernik PH; Diggs CH
    Med Pediatr Oncol; 1977; 3(1):33-40. PubMed ID: 65727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
    Goldhirsch A; Pirovino M; Sonntag RW; Tschopp L; Ryssel HJ; Brunner KW
    Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
    Brusamolino E; Castelli G; Pagnucco G; Orlandi E; Malagó D; Lazzarino M; Bernasconi C
    Haematologica; 1990; 75(4):340-5. PubMed ID: 1703510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABVD chemotherapy of Hodgkin's disease.
    Molnár Z; Schneider T; Várady E; Fleischmann T
    Neoplasma; 1997; 44(4):263-5. PubMed ID: 9473781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dimethyl-triazeno-imidazole-carboxamide (DTIC) in combination chemotherapy for childhood neuroblastoma (author's transl)].
    Mutz ID; Urban CE
    Wien Klin Wochenschr; 1978 Dec; 90(24):867-70. PubMed ID: 741754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Symposium on Hodgkin's Disease. Session 4. Small group workshops. Report on workshop: Chemotherapy.
    Carbone PP
    Natl Cancer Inst Monogr; 1973 May; 36():357-8. PubMed ID: 4126719
    [No Abstract]   [Full Text] [Related]  

  • 17. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
    Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
    Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin's disease: combination chemotherapy in resistant Hodgkin's disease.
    Peterson J; Amare M
    J Kans Med Soc; 1977 Nov; 78(11):466-8. PubMed ID: 72773
    [No Abstract]   [Full Text] [Related]  

  • 19. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-drug combination chemotherapy (MOPP and ABDV) and local radiotherapy for advanced Hodgkin's Disease.
    Case DC; Young CW; Nisce L; Lee BJ; Clarkson BD
    Cancer Treat Rep; 1976 Sep; 60(9):1217-23. PubMed ID: 65221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.